Search Results - "Wei, Andrew"

How I treat acute myeloid leukemia in the era of new drugs by DiNardo, Courtney D., Wei, Andrew H.

“…The acute myeloid leukemia (AML) treatment landscape has changed substantially since 2017. New targeted drugs have emerged, including venetoclax to target…”
Get full text

Towards precision medicine for AML by Döhner, Hartmut, Wei, Andrew H., Löwenberg, Bob

“…With rapid advances in sequencing technologies, tremendous progress has been made in understanding the molecular pathogenesis of acute myeloid leukaemia (AML),…”
Get full text

Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML by Wei, Andrew H., Tiong, Ing S.

“…In 2017, 4 drugs received US Food and Drug Administration marketing approval for acute myeloid leukemia (AML) treatment: targeted therapies for mutant FLT3 and…”
Get full text

BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines by Merino, Delphine, Kelly, Gemma L., Lessene, Guillaume, Wei, Andrew H., Roberts, Andrew W., Strasser, Andreas

“…Defects in apoptotic cell death can promote cancer and impair responses of malignant cells to anti-cancer therapy. Pro-survival BCL-2 proteins prevent…”
Get full text

BCL2 and MCL1 inhibitors for hematologic malignancies by Roberts, Andrew W., Wei, Andrew H., Huang, David C.S.

“…BCL2 and MCL1 are commonly expressed prosurvival (antiapoptotic) proteins in hematologic cancers and play important roles in their biology either through…”
Get full text

Fitness for intensive chemotherapy: a continuing conundrum by Wei, Andrew H.

Get full text

Acute myeloid leukaemia by DiNardo, Courtney D, Erba, Harry P, Freeman, Sylvie D, Wei, Andrew H

“…Progress in acute myeloid leukaemia treatment is occurring at an unprecedented pace. The past decade has witnessed an increasingly improved scientific…”
Get full text

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN by Döhner, Hartmut, Wei, Andrew H, Appelbaum, Frederick R, Craddock, Charles, DiNardo, Courtney D, Dombret, Hervé, Ebert, Benjamin L, Fenaux, Pierre, Godley, Lucy A, Hasserjian, Robert P, Larson, Richard A, Levine, Ross L, Miyazaki, Yasushi, Niederwieser, Dietger, Ossenkoppele, Gert, Röllig, Christoph, Sierra, Jorge, Stein, Eytan M, Tallman, Martin S, Tien, Hwei-Fang, Wang, Jianxiang, Wierzbowska, Agnieszka, Löwenberg, Bob

“…The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults are widely…”
Get full text

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial by Wei, Andrew H., Montesinos, Pau, Ivanov, Vladimir, DiNardo, Courtney D., Novak, Jan, Laribi, Kamel, Kim, Inho, Stevens, Don A., Fiedler, Walter, Pagoni, Maria, Samoilova, Olga, Hu, Yu, Anagnostopoulos, Achilles, Bergeron, Julie, Hou, Jing-Zhou, Murthy, Vidhya, Yamauchi, Takahiro, McDonald, Andrew, Chyla, Brenda, Gopalakrishnan, Sathej, Jiang, Qi, Mendes, Wellington, Hayslip, John, Panayiotidis, Panayiotis

“…Effective treatment options are limited for patients with acute myeloid leukemia (AML) who cannot tolerate intensive chemotherapy. Adults age ≥18 years with…”
Get full text

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia by DiNardo, Courtney D., Pratz, Keith, Pullarkat, Vinod, Jonas, Brian A., Arellano, Martha, Becker, Pamela S., Frankfurt, Olga, Konopleva, Marina, Wei, Andrew H., Kantarjian, Hagop M., Xu, Tu, Hong, Wan-Jen, Chyla, Brenda, Potluri, Jalaja, Pollyea, Daniel A., Letai, Anthony

“…Older patients with acute myeloid leukemia (AML) respond poorly to standard induction therapy. B-cell lymphoma 2 (BCL-2) overexpression is implicated in…”
Get full text

Maintenance therapy for AML: are we there yet? by Wei, Andrew H.

Get full text

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia by DiNardo, Courtney D, Jonas, Brian A, Pullarkat, Vinod, Thirman, Michael J, Garcia, Jacqueline S, Wei, Andrew H, Konopleva, Marina, Döhner, Hartmut, Letai, Anthony, Fenaux, Pierre, Koller, Elizabeth, Havelange, Violaine, Leber, Brian, Esteve, Jordi, Wang, Jianxiang, Pejsa, Vlatko, Hájek, Roman, Porkka, Kimmo, Illés, Árpád, Lavie, David, Lemoli, Roberto M, Yamamoto, Kazuhito, Yoon, Sung-Soo, Jang, Jun-Ho, Yeh, Su-Peng, Turgut, Mehmet, Hong, Wan-Jen, Zhou, Ying, Potluri, Jalaja, Pratz, Keith W

“…In more than 400 older patients with AML who could not receive myeloablative therapy, the incidence of composite complete remission was higher (66.4% vs. 28.3)…”
Get full text

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel by Döhner, Hartmut, Estey, Elihu, Grimwade, David, Amadori, Sergio, Appelbaum, Frederick R., Büchner, Thomas, Dombret, Hervé, Ebert, Benjamin L., Fenaux, Pierre, Larson, Richard A., Levine, Ross L., Lo-Coco, Francesco, Naoe, Tomoki, Niederwieser, Dietger, Ossenkoppele, Gert J., Sanz, Miguel, Sierra, Jorge, Tallman, Martin S., Tien, Hwei-Fang, Wei, Andrew H., Löwenberg, Bob, Bloomfield, Clara D.

“…The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults, published in 2010,…”
Get full text

Targeting MCL-1 in hematologic malignancies: Rationale and progress by Wei, Andrew H., Roberts, Andrew W., Spencer, Andrew, Rosenberg, Aaron Seth, Siegel, David, Walter, Roland B., Caenepeel, Sean, Hughes, Paul, McIver, Zach, Mezzi, Khalid, Morrow, Phuong Khanh, Stein, Anthony

“…Myeloid cell leukemia sequence 1 (MCL-1) is an antiapoptotic protein that plays a key role in promoting cell survival in multiple myeloma (MM), acute myeloid…”
Get full text

Cumulative Haploinsufficiency and Triplosensitivity Drive Aneuploidy Patterns and Shape the Cancer Genome by Davoli, Teresa, Xu, Andrew Wei, Mengwasser, Kristen E., Sack, Laura M., Yoon, John C., Park, Peter J., Elledge, Stephen J.

“…Aneuploidy has been recognized as a hallmark of cancer for more than 100 years, yet no general theory to explain the recurring patterns of aneuploidy in cancer…”
Get full text

MDM2 inhibition: an important step forward in cancer therapy by Konopleva, Marina, Martinelli, Giovanni, Daver, Naval, Papayannidis, Cristina, Wei, Andrew, Higgins, Brian, Ott, Marion, Mascarenhas, John, Andreeff, Michael

“…Targeting the interaction between tumor suppressor p53 and the E3 ligase MDM2 represents an attractive treatment approach for cancers with wild-type or…”
Get full text

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study by Wei, Andrew H, Strickland, Jr, Stephen A, Hou, Jing-Zhou, Fiedler, Walter, Lin, Tara L, Walter, Roland B, Enjeti, Anoop, Tiong, Ing Soo, Savona, Michael, Lee, Sangmin, Chyla, Brenda, Popovic, Relja, Salem, Ahmed Hamed, Agarwal, Suresh, Xu, Tu, Fakouhi, Kaffa M, Humerickhouse, Rod, Hong, Wan-Jen, Hayslip, John, Roboz, Gail J

“…Effective treatment options are limited for patients with acute myeloid leukemia (AML) who cannot tolerate intensive chemotherapy. An international phase Ib/II…”
Get full text

How I Treat patients with AML using azacitidine and venetoclax by Wei, Andrew H, Loo, Sun, Daver, Naval G

“…Venetoclax received full approval in October 2020 for use in older, unfit patients with acute myeloid leukemia (AML) combined with either hypomethylating…”
Get full text

Taking aim at IDH in fitter patients with AML by Wei, Andrew H., Daver, Naval

Get full text

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study by DiNardo, Courtney D, Pratz, Keith W, Letai, Anthony, Jonas, Brian A, Wei, Andrew H, Thirman, Michael, Arellano, Martha, Frattini, Mark G, Kantarjian, Hagop, Popovic, Relja, Chyla, Brenda, Xu, Tu, Dunbar, Martin, Agarwal, Suresh K, Humerickhouse, Rod, Mabry, Mack, Potluri, Jalaja, Konopleva, Marina, Pollyea, Daniel A

“…Elderly patients (aged ≥65 years) with acute myeloid leukaemia have poor outcomes and no effective standard-of-care therapy exists. Treatment with…”
Get full text